NCT06282185 2026-03-23
Superman
Canisius-Wilhelmina Hospital
Phase NA Withdrawn
Clinical Trials
234 trialsNCT04243473 2026-03-03
Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Withdrawn
NCT05014295 2026-02-24
Patient Recall of Cancer Screening and Diagnosis
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT03027986 2026-02-17
PROTOMEN
University Hospital, Rouen
Phase NA Withdrawn
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT03274778 2025-11-18
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Oncology Institute of Southern Switzerland
Phase NA Withdrawn
NCT06060587 2025-10-22
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
Phase 2 Withdrawn
NCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT04645810 2025-10-15
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
University of Rochester
Phase NA Withdrawn
NCT05046782 2025-09-30
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT02869282 2025-09-17
CHEMOPROST
Institut Bergonié
Withdrawn
NCT04580667 2025-08-28
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity
DiaCarta, Inc.
Withdrawn
NCT04569461 2025-07-04
TALON
Duke University
Phase 2 Withdrawn
NCT05333432 2025-06-25
HRPCa-II
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
NCT03477864 2025-04-29
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
Phase 1 Withdrawn
NCT06795178 2025-04-27
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT06795191 2025-04-27
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT03581500 2025-04-23
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05815316 2025-04-13
18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
IRCCS San Raffaele
Phase 2 Withdrawn
NCT06094842 2025-04-01
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT06457854 2025-03-12
PROCeed-BR
AstraZeneca
Withdrawn
NCT04696263 2025-03-10
Single-Port Versus Multi-Port Robotic Radical Prostatectomy
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT02608359 2025-02-03
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
Johnson & Johnson Private Limited
Withdrawn
NCT02905201 2025-02-03
TOGETHER
Janssen Research & Development, LLC
Withdrawn
NCT04495959 2025-01-08
Dynamic Whole Body PET/ MRI
British Columbia Cancer Agency
Withdrawn
NCT05568537 2025-01-03
Prostate MRI and Pylarify PSMA PET/CT
Corewell Health East
Phase 4 Withdrawn
NCT01350180 2024-12-10
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
NCT02588404 2024-12-10
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT02588846 2024-11-18
KOALA
Royal North Shore Hospital
Phase NA Withdrawn
NCT03990194 2024-10-31
LEPTO
RECORDATI GROUP
Withdrawn
NCT06218667 2024-10-31
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn
NCT04312191 2024-10-08
Using Meditation for Oncology Anxiety
Geisinger Clinic
Phase NA Withdrawn
NCT05707182 2024-09-25
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
University of Alabama at Birmingham
Phase EARLY_PHASE1 Withdrawn
NCT03459755 2024-09-19
Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer Survivors
Medical University of South Carolina
Phase NA Withdrawn
NCT05929300 2024-09-19
A Yoga Program for Patients Undergoing Prostate Cancer Surgery
VA Office of Research and Development
Phase NA Withdrawn
NCT06329830 2024-09-19
LUNAAR
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT05415696 2024-08-09
Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
Stanford University
Phase NA Withdrawn
NCT02921373 2024-07-24
TRACK
Western University, Canada
Phase 1 Withdrawn
NCT03035357 2024-05-03
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05807126 2024-05-02
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT04243941 2024-03-21
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03909893 2024-03-19
ARTGU
University Health Network, Toronto
Phase NA Withdrawn
NCT05574712 2024-03-18
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT05034562 2024-03-07
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05156372 2024-02-26
HIIT PCa
The University of Texas Health Science Center at San Antonio
Phase NA Withdrawn
NCT03970863 2024-02-09
Focal Therapy for Localized Prostate Cancer
China Medical University Hospital
Withdrawn
NCT04304079 2024-01-23
A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted Surgery
Chinese University of Hong Kong
Phase NA Withdrawn